Erowid.org: Erowid Reference 8294 : Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile : Feuchtl A, Bagli M, Stephan R, Frahnert C, Kölsch H, Kühn KU, Rao ML

Erowid References Database

Feuchtl A, Bagli M, Stephan R, Frahnert C, Kölsch H, Kühn KU, Rao ML. “Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile”. Pharmacopsychiatry. 2004 Jul 20;37(4):180-8. <a name="ref">Feuchtl A, Bagli M, Stephan R, Frahnert C, Kölsch H, Kühn KU, Rao ML.</a> <a href="/references/8294">"Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile"</a> <i>Pharmacopsychiatry</i>. 2004 Jul 20;37(4):180-8.
Text Abstract (this page) Full Text - English (private) Show Articles by Feuchtl A Bagli M Stephan R Frahnert C Kölsch H Kühn KU Rao ML Article IDs Erowid RefID: 8294 PubMedID: 15467976 Collections Hofmann Collection MDMA Collection All References	Abstract Serotonin plays an important role in psychiatric diseases, most notably in depression and anxiety. Seven different major serotonin receptor subtypes have been described. Receptor-selective agonists and antagonists have been searched for to find a suitable drug to test the in vivo receptor sensitivity. Different serotonin receptor subtypes take part in the control of neuroendocrine function. m-Chlorophenylpiperazine (mCPP) acts as an agonist to serotonin 2C, 1A, 1B, and 1D receptor subtypes and is applied in challenge tests. The object of this study was to develop a pharmacokinetic-pharmacodynamic model to describe the effects of mCPP on pituitary hormone secretion.
Comments and Responses to this Article #
Submit Comment

[ Cite HTML ]